{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:29:27Z","timestamp":1789039767991,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical and Health Program of China Railway","award":["J2023Z608"],"award-info":[{"award-number":["J2023Z608"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62176013"],"award-info":[{"award-number":["62176013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-level public health technical personnel construction Project training plan of Beijing","award":["Subject leader-03-25"],"award-info":[{"award-number":["Subject leader-03-25"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SLAMF8 functions as a cancer-promoting immune checkpoint and could be targeted for therapy in multiple cancer types. Its effect on the immune microenvironment and metastasis of prostate cancer (PCa) is not well understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We analyzed SLAMF8 distribution in PCa and normal tissues using TIMER and examined its role in drug sensitivity and immunotherapy for PCa. The prognostic value and clinical relevance of SLAMF8 in PCa were assessed using multiple datasets. GO, KEGG, and GSEA analyses identified dysregulated pathways in tumors with varying SLAMF8 levels. Tumor purity and immune cell infiltration, and their correlation with SLAMF8 overexpression, were analyzed and confirmed in PCa samples. Additionally, CCK-8, flow cytometry, and transwell assays evaluated the viability, apoptosis, and invasion capacity of SLAMF8-overexpressing PCa cells. Allograft models in C57BL\/6 mice were used to study the effects of SLAMF8 overexpression on tumor growth and immune cell infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to non-tumor tissues, SLAMF8 was overexpressed in PCa tumors. High SLAMF8 levels are linked to poor distant metastasis-free survival (DMFS), higher Gleason scores (GS), and advanced T stage. SLAMF8 expression in PCa tumors negatively correlates with tumor purity but positively correlates with the infiltration of B cells, T cells, dendritic cells, and macrophages. SLAMF8 overexpression in prostate cancer cells promoted cell growth, lowered apoptosis rates, and boosted invasion in vitro, alongside hastening tumor development in mice. This study demonstrates that SLAMF8 enhances PCa metastasis via the TLR4-NF-\u03baB pathway. SLAMF8 is a potential predictor of distant metastasis and a promising target for PCa immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07234-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:20:46Z","timestamp":1761740446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanistic insights into SLAMF8-mediated prostate cancer metastasis via the TLR4-NF-\u03baB pathway"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1824-6232","authenticated-orcid":false,"given":"Qiang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"7234_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363.","journal-title":"Cancer J Clin"},{"key":"7234_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"7234_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Cancer J Clin. 2025;75:10\u201345.","journal-title":"Cancer J Clin"},{"key":"7234_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"H Taitt","year":"2018","unstructured":"Taitt H. Global trends and prostate cancer: A review of Incidence, Detection, and mortality as influenced by Race, Ethnicity, and geographic location. Am J Men\u2019s Health. 2018;12:1807\u201323.","journal-title":"Am J Men\u2019s Health"},{"key":"7234_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","volume":"42","author":"A Ghahremanloo","year":"2019","unstructured":"Ghahremanloo A, Soltani A, Modaresi S, Hashemy S. Recent advances in the clinical development of immune checkpoint Blockade therapy. Cell Oncol (Dordrecht). 2019;42:609\u201326.","journal-title":"Cell Oncol (Dordrecht)"},{"key":"7234_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"J de Bono","year":"2020","unstructured":"de Bono J, Guo C, Gurel B, De Marzo A, Sfanos K, Mani R, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455\u201369.","journal-title":"Nat Rev Cancer"},{"key":"7234_CR7","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.2147\/OTT.S198762","volume":"12","author":"C Zou","year":"2019","unstructured":"Zou C, Zhu C, Guan G, Guo Q, Liu T, Shen S, et al. CD48 is a key molecule of Immunomodulation affecting prognosis in glioma. OncoTargets Therapy. 2019;12:4181\u201393.","journal-title":"OncoTargets Therapy"},{"key":"7234_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","volume":"19","author":"A Dunbier","year":"2013","unstructured":"Dunbier A, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Research: Official J Am Association Cancer Res. 2013;19:2775\u201386.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"7234_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2018.10.015","volume":"204","author":"I Gordiienko","year":"2019","unstructured":"Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP. SLAMF1\/CD150 in hematologic malignancies: silent marker or active player? Clin Immunol (Orlando Fla). 2019;204:14\u201322.","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"7234_CR10","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/cam4.2055","volume":"8","author":"D Wu","year":"2019","unstructured":"Wu D, Zhang P, Ma J, Xu J, Yang L, Xu W, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8:1576\u201383.","journal-title":"Cancer Med"},{"key":"7234_CR11","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1002\/cti2.1347","volume":"10","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Cheng L, Qin Y, Kong L, Shi X, Hu J, et al. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in Gastrointestinal cancers. Clin Translational Immunol. 2021;10:e1347.","journal-title":"Clin Translational Immunol"},{"key":"7234_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00345-011-0690-3","volume":"30","author":"H Kim","year":"2012","unstructured":"Kim H, Bae J, Chang I, Kim K, Lee J, Shin H, et al. Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol. 2012;30:225\u201332.","journal-title":"World J Urol"},{"key":"7234_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00262-010-0931-0","volume":"60","author":"S Gonz\u00e1lez-Reyes","year":"2011","unstructured":"Gonz\u00e1lez-Reyes S, Fern\u00e1ndez J, Gonz\u00e1lez L, Aguirre A, Su\u00e1rez A, Gonz\u00e1lez J, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunotherapy: CII. 2011;60:217\u201326.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"7234_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-017-0688-6","volume":"16","author":"D Ren","year":"2017","unstructured":"Ren D, Yang Q, Dai Y, Guo W, Du H, Song L, et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-\u03baB signaling pathway. Mol Cancer. 2017;16:117.","journal-title":"Mol Cancer"},{"key":"7234_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-017-0645-7","volume":"36","author":"S Huang","year":"2017","unstructured":"Huang S, Wa Q, Pan J, Peng X, Ren D, Huang Y, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-\u03baB signaling in prostate cancer. J Experimental Clin Cancer Research: CR. 2017;36:173.","journal-title":"J Experimental Clin Cancer Research: CR"},{"key":"7234_CR16","doi-asserted-by":"publisher","first-page":"108644","DOI":"10.1016\/j.intimp.2022.108644","volume":"107","author":"W Qin","year":"2022","unstructured":"Qin W, Rong X, Yu C, Jia P, Yang J, Zhou G. Knockout of SLAMF8 attenuates collagen-induced rheumatoid arthritis in mice through inhibiting TLR4\/NF-\u03baB signaling pathway. Int Immunopharmacol. 2022;107:108644.","journal-title":"Int Immunopharmacol"},{"key":"7234_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cns.13041","volume":"25","author":"C Zou","year":"2019","unstructured":"Zou C, Guan G, Zhu C, Liu T, Guo Q, Cheng W, et al. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma. CNS Neurosci Ther. 2019;25:333\u201342.","journal-title":"CNS Neurosci Ther"},{"key":"7234_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s40001-023-01522-8","volume":"28","author":"Q Su","year":"2023","unstructured":"Su Q, Zhu Y, He B, Dai B, Mu W, Tian J. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer. Eur J Med Res. 2023;28:545.","journal-title":"Eur J Med Res"},{"key":"7234_CR19","doi-asserted-by":"crossref","unstructured":"Negar Sadat S, Ali K, Amirhossein M, Amirmohammad M, Mojtaba A, Leili A-M, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med. 2025;25.","DOI":"10.1007\/s10238-025-01751-7"},{"key":"7234_CR20","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"7234_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"7234_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Experimental Clin Cancer Research: CR. 2018;37:327.","journal-title":"J Experimental Clin Cancer Research: CR"},{"key":"7234_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"A Newman","year":"2015","unstructured":"Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"7234_CR24","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"7234_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7234_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u201391.","journal-title":"Behav Res Methods"},{"key":"7234_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"M Garnett","year":"2012","unstructured":"Garnett M, Edelman E, Heidorn S, Greenman C, Dastur A, Lau K, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570\u20135.","journal-title":"Nature"},{"key":"7234_CR28","doi-asserted-by":"crossref","unstructured":"Jia L, Tao F, Di W, Chu X, Ziqin D, Wenpeng C, et al. SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy. Mol Cancer. 2025;24.","DOI":"10.1186\/s12943-025-02308-8"},{"key":"7234_CR29","doi-asserted-by":"crossref","unstructured":"Reham A, Masaki R, Sanaa Shaker A, Takashi Y, Takuto T, Takashi K, et al. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma. Int J Hematol. 2019;110.","DOI":"10.1007\/s12185-019-02649-3"},{"key":"7234_CR30","doi-asserted-by":"crossref","unstructured":"Chunmei Z, Xingjia Z, Huimin L, Qingyu D, Jing S, Baolan S, et al. The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer. Sci Rep, 2024;14.","DOI":"10.1038\/s41598-024-68134-y"},{"key":"7234_CR31","first-page":"45","volume":"38","author":"W Ning","year":"2015","unstructured":"Ning W, Andr\u00e9 V. SLAM family receptors in normal immunity and immune pathologies. Curr Opin Immunol. 2015;38:45\u201351.","journal-title":"Curr Opin Immunol"},{"key":"7234_CR32","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fimmu.2018.01188","volume":"9","author":"T Ou","year":"2018","unstructured":"Ou T, Lilly M, Jiang W. The pathologic role of Toll-Like receptor 4 in prostate cancer. Front Immunol. 2018;9:1188.","journal-title":"Front Immunol"},{"key":"7234_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/pros.22983","volume":"75","author":"S Jain","year":"2015","unstructured":"Jain S, Suklabaidya S, Das B, Raghav S, Batra S, Senapati S. TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. Prostate. 2015;75:1020\u201333.","journal-title":"Prostate"},{"key":"7234_CR34","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.12659\/MSM.906857","volume":"24","author":"W Wang","year":"2018","unstructured":"Wang W, Wang J. Toll-Like receptor 4 (TLR4)\/Cyclooxygenase-2 (COX-2) regulates prostate cancer cell Proliferation, Migration, and invasion by NF-\u03baB activation. Med Sci Monitor: Int Med J Experimental Clin Res. 2018;24:5588\u201397.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"7234_CR35","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1016\/j.molimm.2009.06.016","volume":"46","author":"D Hua","year":"2009","unstructured":"Hua D, Liu M, Cheng Z, Qin X, Zhang H, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46:2876\u201384.","journal-title":"Mol Immunol"},{"key":"7234_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jri.2005.01.005","volume":"66","author":"J Malm","year":"2005","unstructured":"Malm J, Nordahl E, Bjartell A, S\u00f8rensen O, Frohm B, Dentener M, et al. Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes. J Reprod Immunol. 2005;66:33\u201343.","journal-title":"J Reprod Immunol"},{"key":"7234_CR37","doi-asserted-by":"crossref","unstructured":"Seyed Sobhan B, Akram A, Elham R, Mohammad Sharif S, Mojtaba A. Meta-analytical and meta-regression evaluation of subclinical hyperthyroidism\u2019s effect on male reproductive health: hormonal and seminal perspectives. Reprod Sci. 2024;31.","DOI":"10.1007\/s43032-024-01676-8"},{"key":"7234_CR38","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1101\/gad.197590.112","volume":"26","author":"AG Luke","year":"2012","unstructured":"Luke AG, Michael TH. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev. 2012;26:1758\u201368.","journal-title":"Genes Dev"},{"key":"7234_CR39","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1101\/gad.284851.116","volume":"30","author":"HB Eric","year":"2016","unstructured":"Eric HB, Luke AG, Michael TH. A senescence secretory switch mediated by PI3K\/AKT\/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 2016;30:1811\u201321.","journal-title":"Genes Dev"},{"key":"7234_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","volume":"26","author":"T Koji","year":"2014","unstructured":"Koji T, Michael K. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54\u201374.","journal-title":"Semin Immunol"},{"key":"7234_CR41","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","volume":"12","author":"HB Eric","year":"2021","unstructured":"Eric HB, Luis RM-B, Iris Z, Daniel RG, Julia F, Michael TH. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun. 2021;12:6218.","journal-title":"Nat Commun"},{"key":"7234_CR42","doi-asserted-by":"crossref","unstructured":"Mehdi T, Mojtaba A, Najmaldin S, Mohammad AV, Saeid B, Bita B. The association of nasal and blood eosinophils with serum IgE level in allergic rhinitis and asthma: a case-control study. Health Sci Rep. 2024;7.","DOI":"10.1002\/hsr2.70191"},{"key":"7234_CR43","doi-asserted-by":"crossref","unstructured":"Leila R, Mostafa E, Seyed Amin M, Hamed SS, Gholamreza K, Mojtaba A. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52.","DOI":"10.1007\/s11033-024-10200-9"},{"key":"7234_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13062-023-00380-y","volume":"18","author":"B Wei","year":"2023","unstructured":"Wei B, Su Z, Yang H, Feng Y, Meng C, Liang Z. Inhibition of TRAF6 improves hyperlipidemic acute pancreatitis by alleviating pyroptosis in vitro and in vivo rat models. Biol Direct. 2023;18:23.","journal-title":"Biol Direct"},{"key":"7234_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jcp.21787","volume":"220","author":"E Ang","year":"2009","unstructured":"Ang E, Pavlos NJ, Rea SL, Qi M, Chai T, Walsh JP, et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol. 2009;220:450\u20139.","journal-title":"J Cell Physiol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07234-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:20:52Z","timestamp":1761740452000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07234-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7234"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07234-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human experiments were approved by the Ethics Committee of Beijing Shijitan Hospital, Capital Medical University (Approval No. IIT2024-091-002). Animal experiments were approved by the Ethics Committee of Beijing Shijitan Hospital (Approval No. KYD-2024-0070-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1189"}}